is regulated primarily by post-transcriptional mechanisms controlled by several metabolic and nutritional factors (for a recent review, see Ref. 2 ).
Apolipoprotein B100 (apoB) is the major protein present on VLDLs and is required for the assembly and secretion of VLDL from the liver ( 1 ) . VLDL is the precursor of LDL, and its overproduction is characteristic of insulin-resistant states ( 1 ) . The number of VLDL particles secreted by the liver is dependent on the intracellular level of apoB, which buffer [10 mM Hepes (pH 7.4), 250 mM sucrose, 0.5 mM DTT, 1× EDTA-free protease-inhibitor cocktail, 20 U/ml RNase inhibitor, 200 µM BHT, 2.5 mg/ml trypsin inhibitor, 2 mM MgCl 2 ]. Cells were then homogenized by nitrogen decompression in a cell disruption bomb (500 psi for 15 min). Typically, cells from two P100 dishes were used for homogenization per experimental treatment. The homogenates were centrifuged at 10,000 g for 10 min to obtain the postnuclear supernatant, also referred to as postmitochondrial supernatant. The postnuclear supernatant was centrifuged at 100,000 g for 1 h at 4°C to obtain total microsomes. Purifi ed Golgi microsomes were used in some experiments instead of total microsomes and were isolated as described ( 10, 11 ) . Luminal contents of total and Golgi microsomes were released by treatment with 0.1 M sodium carbonate (pH 11) and deoxycholic acid (0.025%) (10) (11) (12) . The supernatants containing the released lipoproteins were recovered by centrifugation at 60,000 rpm for 60 min at 4°C in a Beckman TLA 100.4 rotor. Luminal lipoproteins and those from conditioned media were separated according to density by sucrose-gradient ultracentrifugation ( 10, 11 ) .
Immunoprecipitation and analysis [ 35 S]labeled apoB from each density fraction was immunoprecipitated using rabbit anti-rat apoB antiserum and separated in duplicate on two 4% gels: one set was subjected to fl uorography, and the other was subjected to apoB quantifi cation by scintillation counting. For scintillation counting of the [
35 S] label associated with apoB in each density fraction, the corresponding bands were excised from the gel and solubilized by SOLVABLE, and the associated radioactivity was measured using a Beckman LS 6000 scintillation counter after the addition of scintillation fl uid. ApoB data from fl uorograms were quantifi ed by densitometry and adjusted for differences in exposure times.
Analysis of apoB-aggregates was performed as described in the fi gure legends after immunoprecipitation from whole cell lysates prepared in buffer containing 6 mM Na 2 HPO 4 , 4.5 mM NaH 2 PO 4 , 125 mM NaCl, 36 mM lithium dodecyl sulfate, 24 mM deoxycholate, and 1% Triton X-100 (pH 7.4). All apoB measurements obtained by scintillation counting were normalized to trichloroacetic acid (TCA)-precipitable radioactivity as a measure of total protein synthesis. Cellular TCA counts were also adjusted for total cell protein (TCA counts/mg) to account for variations in cell numbers among experimental treatments.
Confocal microscopy
McA cells were treated as described, fi xed with 4% paraformaldehyde, and permeabilized with 0.1% saponin before the addition of antisera or antibodies. ApoB immunostaining was performed using the same antibody used for the immunoprecipitation experiment (rabbit anti-rat apoB at 1:250). The cells were stained for several markers: LAMP1 (lysosome marker) using the purifi ed mouse antibody from Stressgen (Victoria, Canada) at 1:1,000, ␥ -tubulin using the mouse anti-␥ -tubulin antibody (ref#T5326) at 1:5,000, and goat anti-vimentin antibody (ref#V4630) 1:100 from Sigma Aldrich (Munich, Germany). The staining was revealed after incubation with alexa-fl uor (488 and 594) conjugated antibodies (Invitrogen) directed against the specifi c species. The stained cells were examined with a Leica TCS SP5 confocal laser scanning microscope.
Statistical analysis
Data reported are displayed as mean ± SEM, with the number of independent experiments provided in the fi gure legends. At least three replicates were performed for each independent experiment. Signifi cance was calculated by two-tailed t -tests or of apoB turnover. The data are consistent with the transit of apoB from the ER to the Golgi as a pre-VLDL particle, which fails to fully mature and is shunted to autophagy. These results support a more general model in which pre-VLDL particles that do not mature properly are removed from the secretory pathway by a late-stage quality control program.
EXPERIMENTAL PROCEDURES

Materials
Rat hepatoma cell line McA-RH7777 (McA) was obtained from ATCC (Manassas, VA). Cell culture media and reagents were from Gibco/Invitrogen (Carlsbad, CA) and Cellgro (Herndon, VA). Rabbit polyclonal antiserum to rat apoB was developed in the author's laboratory. Rabbit anti-LC3 polyclonal antibody (free and cross-linked to Dynabead-Protein A) was provided by the laboratory of Dr. Zemin Yao (University of Ottawa). Rabbit anti-calnexin antibody was purchased from Stressgen (Ann Arbor, MI). Protein-A Sepharose was from Amersham Pharmacia Biotech (Piscataway, NJ). [ 
Cell culture
McA cells were regularly maintained at 37°C/5% CO 2 in DMEM supplemented with 10% FBS, 10% horse serum (HS), 1% L-glutamine, and 1% penicillin/streptomycin on P100 dishes coated with type I collagen. Medium was changed every 3 days, and cells were used for experiments at 90-95% confl uence. For some experiments, cells were also grown on 6-well plates.
Cell treatments and metabolic labeling
Cells were pretreated for 1 h with 0.6 mM DHA-BSA or 0.6 mM DHA-BSA with or without 100 µM desferrioxamine (DFX) to inhibit lipid peroxidation in Met/Cys-free DMEM supplemented with 0.5% FBS, 0.5% HS, 1% L-glutamine, and 1% penicillin/ streptomycin. In all experiments, treatment with 0.6 mM OA-BSA was used as the reference. After preincubation, cells were pulselabeled with 240 µCi [ 35 S]Met/Cys for 10 min in the same medium. The pulse medium was then removed, and cells were washed quickly with PBS (2×) and chased in medium containing excess unlabeled Met (10 mM)/Cys (3 mM), 0.5% FBS, 0.5% HS, 1% L-glutamine, 1% penicillin/streptomycin, and the corresponding fatty acid treatments. The end of pulse was characterized as 0 min of chase (T0). Other chase time points were 15 min (T15), 30 min (T30), 45 min (T45), 60 min (T60), and 90 min (T90). At the end of each chase time point, the conditioned media and cells were collected. In some experiments, cells were labeled to steady-state in which fatty acid treatments were administered in the presence of 100 µCi [
35 S]Met/Cys for 3 h after the 1-h preincubation. In one series of experiments, pulse-chase studies as described above were carried out at 20°C to block protein traffi cking out of the Golgi. microsomal apoB appeared to be secreted associated with VLDL by 60 min from OA-treated cells.
To better clarify the effects of OA and DHA on pre VLDL conversion to VLDL and on apoB degradation, the data from Fig. 1A and B were expressed as the sum of apoB recovered from the corresponding density fractions of the microsomal and media samples. After T30 there was a decrease in pre-VLDL apoB in OA-treated cells and a corresponding increase in VLDL-apoB, strongly suggesting a precursor-product relationship ( Fig. 1C) . A similar precursor-product relationship was not observed in DHA-treated cells over the same time period ( Fig. 1C ) . Furthermore, in pulse-chase experiments, there was a signifi cant reduction of total apoB recovery to 26.4 ± 3.93% at T90 compared with T0 [comparable to what we have previously reported ( 3, 6) ], whereas no signifi cant degradation was seen in OA-treated cells. Thus, in OA-treated cells, pre-VLDL appears to be converted to and secreted as mature VLDL. In contrast, in DHA-treated cells, luminal loss of pre-VLDL did not seem to be associated with conversion to VLDL, nor was apoB quantitatively secreted into the medium, suggesting either a failure of VLDL maturation or the degradation of pre-VLDL or mature VLDL particles in DHAtreated cells. These possibilities were further explored in the following series of experiments.
Blocking intracellular lipid peroxidation by DFX enables conversion of pre-VLDL to VLDL and its secretion in DHA-treated cells
The mechanism of DHA-induced apoB degradation involves the formation of lipid peroxides and reactive oxygen species ( 6, 7 ) . DFX has been shown to be a potent inhibitor of DHA-induced apoB degradation by preventing lipid peroxidation ( 5, 6 ) . In the presence of DFX, the analysis of microsomal luminal lipoproteins revealed that DHA-treated cells were able to form pre-VLDL particles and convert them into mature VLDL ( Fig. 2 ) . Indeed, similar quantities of luminal VLDL were recovered from cells treated with OA and DHA+DFX at T45 and T60 (see graphs in Fig. 2A, B ) . The luminal VLDL from DHA+DFX-treated cells was subsequently recovered from the medium, and the density distribution of apoB-containing lipoproteins was similar to that in OA-treated cells at these time points (see the representative fl uorograms in Fig. 2A, B ) . These results indicate that the decreased appearance of mature VLDL in DHA-treated hepatocytes was related to lipid peroxidation.
Blocking apoB-aggregation by inhibiting Golgi exit prevents loss of pre-VLDL but does not restore VLDL formation in DHA-treated cells
We have shown ( 5 ) that lipid peroxidation leads to the formation of apoB aggregates (confi rmed by mass spectrometry) that appear near the top of the SDS-PAGE gels coincident upon or after exiting from the Golgi. These aggregates are not observed in signifi cant levels in cells with relatively low levels of lipid peroxidation (i.e., cells incubated with BSA or OA or cotreated with DHA+DFX) ( 5 ). In addition, blocking Golgi exit using a 20°C incubation ANOVA with Dunnett or Bonferroni post-testing for multiple comparisons. A P value of <0.05 was considered signifi cant.
RESULTS
Reduced secretion of mature (fully lipidated) VLDL from DHA-treated hepatocytes is associated with reduced recovery of VLDL-associated apoB from the microsomal lumen
Although McA cells secrete apoB100 and apoB48, herein the abbreviation "apoB" refers only to apoB100. We did not analyze apoB48 data because they are not relevant to hepatic VLDL in the human liver (which only produces apoB100) and apoB48 also does not undergo marked degradation in rodent hepatic cells in response to fi sh oil fatty acids ( 3 ) .
A time course of VLDL formation and secretion by DHA-treated cells was performed by a pulse-chase protocol in conjunction with density fractionation from microsomes isolated at the time points indicated in Fig. 1 . Metabolically labeled apoB from total microsomes ( Fig. 1A ) and the conditioned media ( . Of these, apoB-containing particles in fractions 6 through 11, in which are found the precursor particles to VLDL, were classifi ed as "pre-VLDL" ( 1, 13 ) .
For the apoB-containing lipoproteins isolated from the microsomal lumens, by T30 ( Fig. 1A ) , although similar levels of luminal VLDL-apoB were recovered from both treatments, differences emerged in the other density subfractions. OA-treated cells demonstrated a distinct peak of HDL-apoB, whereas DHA treatment resulted in two peaks, one of HDL density and the other of LDL density. By T60 ( Fig. 1A ) , the differences in lipoprotein density profi les were even more striking. There was a decrease in the HDL-density (pre-VLDL precursor) particles in the case of OA, with evidence that some were being converted to VLDL (note the increase in apoB recovery in fraction 1). DHA-treated cells also showed a decrease in microsomal apoB associated with HDL-density particles, but this was part of a broad decrease across all of the density fractions.
With both treatments, there was overall loss of apoB from the microsomes over time, and by examining the lipoproteins in the conditioned media samples, we were able to determine whether this was attributable to secretion. OA-treated cells secreted apoB almost entirely as mature VLDL ( Fig. 1B ) . Consistent with previous studies (e.g., Ref. 4 ), apoB secretion from DHA-treated cells was signifi cantly less than from OA-treated cells and was mainly as LDL-density particles ( Fig. 1B ) . The fi rst appearance of metabolically labeled apoB in the medium was VLDL associated from OA-treated cells at T30 ( Fig. 1B ) . By considering the data in Fig. 1A and B together, the majority of 
37°C, the loss of apoB from the microsomal lumen was mainly accounted for by a deficiency of apoB associated with mature VLDL ( Fig. 3A ) . Because the loss of pre-VLDL particles as a result of apoB aggregation could be the basis for reduced VLDL maturation with DHA treatment, we tested whether a 20°C temperature block would restore VLDL formation. To investigate this, the 45 min chase was also conducted at 20°C ( Fig. 3B ) . Similar to 37°C, equivalent amounts of pre-VLDL particles were isolated from microsomes isolated from cells treated with DHA and OA at 20°C (compare Figs. 3A  and 3B ). The 20°C temperature block also restored total apoB levels in DHA-treated cells to levels comparable to OA-treated controls (77.67 ± 4.47% of OA at 20°C compared with 57.62 ± 0.43% of OA at 37°C). However, VLDL apoB recovery (i.e., the sum of apoB in all intracellular and secreted density fractions) was determined by fl uorography and densitometry. A: Density distribution profi les at T30 and T60 of apoB-lipoproteins isolated from total microsomes of cells treated with DHA or OA. B: Secreted apoB at T30 and T60. Fraction 1 corresponds to mature (fully lipidated) VLDL density particles, and fractions 6 through 11 correspond to pre-VLDL particles. Below each graph are the corresponding representative fl uorograms. Results shown are representative of three separate experiments. C: Top two graphs: Percentage of apoB associated with the pre-VLDL and VLDL fractions at 0, 15, 30, 45, 60, and 90 min of chase (T0, T15, T30, T45, T60, and T90, respectively) from cells treated with OA or DHA. Bottom graph: Total apoB recovery at the end of chase. a and b indicate a signifi cant decrease in pre-VLDL-apoB or increase in VLDL-apoB from T30 to T60, respectively ( P < 0.05); c indicates a signifi cant reduction in apoB recovery from T0 to T90 with DHA ( P < 0.05). The results in C are based on three independent experiments for T30, T45, and T60; two independent experiments for T15; and replicate measurements from one experiment for T0 and T90. 
of temperature (46.12 ± 3.74% of OA at 20°C and 59.42 ± 5.04% of OA at 37°C). DFX cotreatment with DHA was able to restore VLDL formation to control (OA) levels.
Although VLDL maturation was impaired in the DHAtreated cells, we wondered whether the fate of the smaller number of pre-VLDL particles that did successfully convert resembled that of the mature VLDL in OA-treated cells. Therefore, we examined the total VLDL-apoB recovery data at each chase time point from 0 to 90 min. The total VLDL-apoB recovered at 90 min compared with that recovered at earlier time points for the OA and DHA treatments did not indicate signifi cant degradation of apoB associated with mature VLDL (data not shown). These data imply that once pre-VLDL particles were converted to mature VLDL in OA or DHA-treated cells, they were quantitatively secreted.
We ( 10, 11 ) and others (e.g., Ref. 1, 15 ) have shown that much of the maturation of VLDL particles occurs in the Golgi. We have assumed this to be the case in our experiments using total microsomes, which are a mixture of ER and Golgi-derived structures. To directly examine events in the Golgi, we repeated the 45 min time point with isolated Golgi microsomes ( Fig. 4 ) . The pattern of results, including the effects of DFX, was similar to that observed with total microsomes (i.e., less VLDL maturation in DHA-treated cells and its restoration upon DFX cotreatment).
Loss of VLDL formation and secretion coincides with the formation of intracellular apoB aggregates in DHA-treated cells, which colocalize with lysosomes in a microtubule-dependent, aggresome-independent process
To further investigate the nature of the intracellular loss of monomeric (i.e., nonaggregated) apoB associated with pre-VLDL in DHA-treated cells, we carried out another series of pulse-chase studies. ApoB aggregates started to appear by T30 ( Fig. 5 ) and accumulated over time, with greater quantities observed at 45 min ( Fig. 5 ; T45 = 1.5× the levels at T30) and increasing further at T60 ( Fig. 5 ; T60 = 3× T30). Although there were some aggregates in OA-treated cells, they did not accumulate over time ( Fig. 5 ) . The time course of apoB aggregate accumulation in DHA-treated cells parallels the decrease in the recovery of mature VLDL from the microsomes and conditioned media. The aggregates are recovered from whole cell lysate and never from microsomes, consistent with the post-Golgi formation we previously reported ( 5 ).
We next turned to the intracellular fate of the aggregated apoB. From previous studies, including coimmunoprecipitation analysis, we know that this material eventu ally becomes associated with autophagosomes ( 5 ). We hypothesized that like some other proteins, these aggregates fi rst accumulate in cytosolic structures called aggresomes, which can be transported by the microtubule network to the juxta-nuclear region, where they are packaged into autophagosomes ( 16 ) . In DHA-treated cells, this would mean that apoB and its associated lipoprotein particles would be fi rst extruded from the Golgi and would then aggregate and be traffi cked in a non-vesicular structure to the juxtanuclear region, where they would fuse with autophagosome precursors. Alternatively, autophagosomes (perhaps originating from Golgi membranes) would fi rst form around apoB and its associated particles, without the requirement of aggresome formation/transport, and then be clustered in the juxta-nuclear region by microtubuledependent transport before fusion with lysosomes. To investigate these possibilities, we performed immunofl uorescence studies.
First, we confi rmed that the lysosomes, the site of aggregate degradation in either scenario, were associated with apoB in DHA-treated cells. More immunostained apoB colocalized with LAMP1 (a standard marker of lysosomes) in the presence of DHA compared with hepatic cells treated with BSA, OA, or any of the conditions in the presence of DFX ( Fig. 6A and supplementary Fig. I ) . The colocalization was also increased by cotreating the cells with NH 4 Cl-leupeptin, a standard condition used to block the degradation of proteins in lysosomes. In contrast, there was the absence of colocalization in cells pretreated with 3-methyl adenine (3-MA), which prevents autophagosome formation, before incubation with DHA ( Fig. 6A ) , or, as noted 
DISCUSSION
Although it is well established that fi sh oil fatty acids (DHA, EPA) reduce plasma levels of triglycerides and apoB associated with VLDL, there are multiple mechanisms put forward to explain these effects. Clinical kinetic studies have shown that diets rich in fish oil decrease hepatic production of VLDL-apoB100 (e.g., Ref. 19 ). Based on our previous studies (reviewed in Ref. 20 ) , one such mechanism for this is the stimulation by fi sh oil fatty acids of apoB degradation by autophagy. In the present set of studies, we have extended the understanding of fi sh oil-stimulated degradation of apoB by showing that: 1 ) DHA treatment impairs the full lipidation of pre-VLDL particles in the Golgi, 2 ) this impairment depends on lipid peroxidation and precedes apoB aggregation, and 3 ) apoB associated with the immature particles destined for degradation does not undergo aggresome formation in the cytosol before capture by autophagosomes.
above, in cells cotreated with DFX ( Fig. 6A and supplementary Fig. I ), which prevents DHA-induced lipid peroxidation and apoB aggregation.
To assess the involvement of the microtubule network, which would be expected to play a role in the autophagy of apoB and its associated lipoproteins in either scenario described above, we pretreated the cells with DHA for 2 h before adding the microtubule dispersing agent nocodazole. There was an obvious decrease in apoB-LAMP1 colocalization in the treated cells ( Fig. 6B) . To differentiate between microtubule-mediated transport of an aggresome vs. an autophagosome, we looked for colocalization of apoB with ␥ -tubulin and vimentin, proteins known to associate with aggresomes ( 17, 18 ) . Immunostained apoB did not colocalize with either marker ( Fig. 6C) . Taken with our fi nding that apoB aggregation in DHA-treated cells requires traffi cking from the Golgi ( 5 ), the data favor the idea that aggregation occurs not as part of a cytosolic aggresomal process but after the incorporation into autophagosomes of apoB-lipoproteins that failed to mature in the Golgi. Fig. 3 . DHA-treated hepatocytes are able to form pre-VLDL particles but convert fewer to mature VLDL than OA-treated cells. Cells were treated as in Fig. 2 , except that the experiment was concluded after 45 min of chase. A: The sum of apoB recovered from fractions 6 through 11 (pre-VLDL) or fraction 1 (fully lipidated VLDL) from total microsomes of cells treated with OA, DHA, or DHA+DFX at 37°C, as well as the total apoB recovered, are shown. * P < 0.05 compared with OA. B: The corresponding data were obtained from an experiment carried out at 20°C, with representative fl uorograms also shown. * P < 0.01 compared with OA. Graphical results shown are from three separate experiments at 37°C and two separate experiments at 20°C, with replicate measurements for each treatment. The experimental approach we took was based on previous reports that showed in rat hepatic cells the sequential formation of HDL-density pre-VLDL particles in the ER and their conversion to mature VLDL-density particles in the Golgi (e.g., Refs. 11, 12, 15 ) . In the current set of studies, we replicated these fi ndings with OA, but in DHA-treated cells, there was the initial formation in the ER of pre-VLDL particles but little conversion in the Golgi to mature (i.e., fully lipidated) lipoproteins (consistent with Ref. 21 ). Instead, there was apoB aggregation and degradation. The defi ciency of VLDL maturation in DHA-treated cells is unlikely to be a consequence of inadequate lipid synthesis, which is at least that stimulated by OA (e.g., Refs. 4, 21, 22 ) . Because blocking Golgi exit prevented the loss of pre-VLDL particles ( Fig. 3 ) and the formation of apoB aggregates ( 5 ), aggregation and degradation of apoB associated with pre-VLDL in DHAtreated cells appears to occur post-Golgi. This is consistent with the lack of aggregates in microsomes and with the data shown in Fig. 6 . In general, the data do not support the hypothesis that the loss of pre-VLDL without its quantitative secretion or conversion to mature VLDL followed apoB-aggregation/degradation. Instead, the fi ndings that inhi biting apoB aggregation did not restore VLDL maturation ( Fig. 3 ) and that removal of the 20°C block resulted in formation of aggregates ( 5 ) suggest that aggregation and degradation are consequences of derangements in apoB and pre-VLDL metabolism.
The data in Fig. 6 further argue that the large aggregates that form in DHA-treated cells do not represent a process in which apoB is extruded from the Golgi into the cytosol and fi rst assembled into an aggresome before being taken up by autophagosomes. Rather, more likely is the transfer directly of apoB associated with immature lipoprotein particles to autophagosomes, with subsequent aggregation in the lower pH environment. One possible factor involved in the transfer of "failed" VLDL intermediates is the autophagy-related protein Atg9, which has been shown to promote the recruitment of components of autophagosome isolation membranes from the Golgi apparatus ( 23, 24 ) . In experiments in which we knocked down Atg9 mRNA, however, we found only a minor effect (<20%) on the degradation of apoB aggregates in DHA-treated cells (U. Andreo, E. Fisher, unpublished observations ). It will be an important goal of future experiments to implicate other candidate factors. this scenario comes from a number of other reports. For example, Boren at al. (12) and Stillemark-Billton et al. (26) found that HDL-density apoB particles (i.e., pre-VLDL) were degraded intracellularly unless further lipidated, although the degradative process was not recognized. In a The identifying feature of apoB to be targeted for autophagy in DHA-treated cells may be its modifi cation by lipid peroxides during its residence in the secretory pathway. One obvious circumstance favoring apoB modifi cation by lipid peroxides is their incorporation into the lipid fraction of nascent lipoprotein particles, which would place them in intimate contact with the protein. This is supported by fi nding more ( ‫ف‬ 1.5×) thiobarbituric acid reactive substances (a measure of lipid peroxidation) in lipoproteins isolated from Golgi microsomes from DHAtreated cells than in those isolated from OA-treated cells (V. Maitin, E. Fisher; unpublished observations ). Other opportunities for fi sh oil fatty acids to disrupt apoB/pre-VLDL metabolism are afforded by the effects of the type of fatty acid on the composition of cellular membranes (plasma and endo) and the functions of transmembrane proteins. For example, it has been shown that phospholipids become enriched in EPA in microsomal membranes in EPA-treated McA cells ( 21 ) . Such enrichment may disrupt the necessary association of pre-VLDL with endomembranes, which serves to lipidate apoB-lipoproteins in hepatic cells (e.g., Ref. 12, 15, 25 ) or may impair the utilization of triglycerides that are derived from phospholipid remodeling for VLDL lipidation ( 21 ) .
In summary, the present data suggest a model in which pre-VLDL particles that "pass" ER-quality control criteria but then "fail" similar scrutiny in the Golgi if they do not properly mature are targeted for degradation by autophagy. Besides our results for DHA, further support for Fig. 5 . Loss of monomeric apoB from the microsomal lumen coincides with the formation of intracellular apoB aggregates. Cells were treated as in Fig. 1 , except that immunoprecipitation/SDS-PAGE analysis for apoB was performed using aliquots of the cell lysates at the chase time points 30, 45, and 60 min. The aggregated apoB (which appears toward the top of the gels) was quantifi ed by densitometry. a = signifi cant increase compared with OA30 ( P < 0.05 for DHA30; P < 0.01 for DHA45 and DHA60); b = signifi cant increase compared with DHA30 ( P < 0.01); c = signifi cant increase compared with DHA45 ( P < 0. more recent study, it was shown that a naturally occurring mutation of apoB (apoB A31P) associated with hypolipidemia was traffi cked from the ER to the Golgi, where it failed to be lipidated, and was subsequently degraded by autophagy ( 27 ) . In another example, Brown and Gibbons (28) reported that insulin, which is known to induce autophagic degradation of apoB ( 29 ), interferes with VLDL particle maturation. It has been previously thought that the major quality control of secretory proteins is exerted in the ER. For the majority of proteins, this is probably true, but in the case of VLDL (and perhaps other cargoes that undergo significant assembly/maturation events post-ER), mechanisms to exert quality control late in the secretory pathway are also needed. Thus, the continued investigation of VLDL secretory control will not only inform the fi eld of lipoprotein metabolism, but will more generally expand the understanding of the cellular regulation of protein secretion.
